{"protocolSection":{"identificationModule":{"nctId":"NCT03263117","orgStudyIdInfo":{"id":"HSC-MS-17-0436"},"organization":{"fullName":"The University of Texas Health Science Center, Houston","class":"OTHER"},"briefTitle":"SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke","officialTitle":"SEGA - SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke - a Randomized Comparative Effectiveness Trial.","acronym":"SEGA"},"statusModule":{"statusVerifiedDate":"2023-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-07-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-04-22","type":"ACTUAL"},"completionDateStruct":{"date":"2023-04-22","type":"ACTUAL"},"studyFirstSubmitDate":"2017-08-16","studyFirstSubmitQcDate":"2017-08-23","studyFirstPostDateStruct":{"date":"2017-08-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-05-10","lastUpdatePostDateStruct":{"date":"2023-05-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Peng Roc Chen, MD","investigatorTitle":"Professor in Neurosurgery","investigatorAffiliation":"The University of Texas Health Science Center, Houston"},"leadSponsor":{"name":"The University of Texas Health Science Center, Houston","class":"OTHER"},"collaborators":[{"name":"Stryker Neurovascular","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"Objectives:\n\nThis study aims to estimate overall treatment benefit (improvement in disability) among acute ischemic stroke patients that are randomized to General Anesthesia (GA) compared with Sedation (CS) during endovascular therapy. Assess safety (as measured by incidence of symptomatic intracranial hemorrhage); rates of Endovascular therapy (EVT) procedural complications, reperfusion; and quality of life.\n\nHypothesis:\n\nGA during EVT for acute ischemic stroke improves functional outcomes at 90 days compared to sedation."},"conditionsModule":{"conditions":["Stroke"],"keywords":["Acute stroke","Cerebral Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":260,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Sedation","type":"ACTIVE_COMPARATOR","description":"The protocol does not specify a particular combination of drugs that must be used for sedation. The choice of specific drugs and dosages for achieving sedation will be up to the anesthesiologist.","interventionNames":["Drug: Sedation","Procedure: Intra-arterial Thrombectomy"]},{"label":"General Anesthesia","type":"ACTIVE_COMPARATOR","description":"The protocol does not specify a particular combination of drugs that must be used for general anesthesia. The choice of specific drugs and dosages for achieving general anesthesia will be up to the anesthesiologist.","interventionNames":["Drug: General Anesthesia (GA)","Procedure: Intra-arterial Thrombectomy"]}],"interventions":[{"type":"DRUG","name":"Sedation","description":"The protocol does not specify a particular combination of drugs that must be used for sedation.\n\nThe most common drugs utilized for sedation and wide dosing ranges are included in the protocol (i.e., sedation will be provided under the supervision of an anesthesiologist and may use a combination of fentanyl, midazolam, dexmedetomidine infusion (with or without loading dose), and/or low-dose propofol by intermittent bolus or infusion); however, the choice of specific drugs and dosages for achieving conscious sedation or general anesthesia will not be specified by the protocol but will be up to the anesthesiologist.","armGroupLabels":["Sedation"]},{"type":"DRUG","name":"General Anesthesia (GA)","description":"The protocol doesn't specify drugs that must be used for GA, the choice of drugs and dosages for achieving general anesthesia will not be specified by the protocol but will be up to the anesthesiologist.\n\nThe most common drugs utilized for GA and wide dosing ranges included in the protocol are (GA will be provided under the supervision of an anesthesiologist and induction of anesthesia may be achieved with propofol and/or etomidate; muscle paralysis may be achieved with succinylcholine or non-depolarizing paralytic (rocuronium or vecuronium); and adjuvant lidocaine and fentanyl; if intravenous maintenance of anesthesia is used, it may be achieved by propofol infusion at 50 to 150 mcg/kg/min with redosing of non-depolarizing paralytic and fentanyl as needed; if inhalational maintenance of anesthesia is used it will be achieved with sevoflurane 1% to 2% or desflurane 3% to 6% end-tidal concentration with redosing of non-depolarizing paralytic and fentanyl as needed)","armGroupLabels":["General Anesthesia"]},{"type":"PROCEDURE","name":"Intra-arterial Thrombectomy","description":"The first line therapeutic embolectomy device should be a stent retriever. Additional Endovascular therapies including, but not limited to, intra- or extracranial angioplasty ± stenting; antithrombotics (oral, IV or IA antiplatelets or anticoagulants) intra-arterial thrombolytics; are left to the decision of the local treatment team.","armGroupLabels":["General Anesthesia","Sedation"],"otherNames":["Endovascular Therapy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"modified Rankin Scale (mRS)","description":"Comparison of independent clinical outcome as measured by the modified Rankin Scale (mRS) at 90 days (scores 5 and 6 combined) among patients randomized to GA versus Sedation assessed by study personnel blinded to treatment.","timeFrame":"90 days"}],"secondaryOutcomes":[{"measure":"Dichotomized modified Rankin Scale (mRS)","description":"Dichotomized modified Rankin Scale (mRS) at 90 days (0-2 vs 3-6) adjusted for stratification variable","timeFrame":"90 days"},{"measure":"Rates of recanalization","description":"Rates of recanalization using modified TICI scores","timeFrame":"post procedure within 6 hours"},{"measure":"National Institute of Health Stroke Scale (NIHSS) scale","description":"Early clinical improvement measured by difference NIHSS scale","timeFrame":"24-36 hours post procedure"},{"measure":"modified Rankin Scale (mRS)","description":"Independent functional outcome in General Anesthesia patients treated with inhalational vs. intravenous medications.","timeFrame":"90 days"},{"measure":"Quality of life as assessed by the European Quality of Life-5 Dimensions (EQ-5D) instrument","timeFrame":"90 days"},{"measure":"Incidence of symptomatic intracerebral hemorrhage","description":"Safety measured by incidence of symptomatic intracerebral hemorrhage","timeFrame":"18-36 hours post procedure"},{"measure":"Incidence of mortality","description":"Safety measured by incidence of mortality","timeFrame":"18-36 hours post procedure"},{"measure":"Incidence of device related complications","description":"Safety measured by incidence of device related complications","timeFrame":"18-36 hours post procedure"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Acute ischemic stroke due to large intracranial vessel occlusion demonstrated on CT-angiography in the following anterior circulation locations that will be treated by endovascular therapy (EVT):\n\n   1. Internal Carotid Artery (terminal \"T\" or \"L-type\"- occlusion)\n   2. Middle Cerebral Artery (MCA) M1 or proximal M2\n   3. Anterior Cerebral Artery (ACA) A1 or proximal A2\n\n      * Patients who receive IV-tPA thrombolysis are eligible provided the drug was delivered within 4.5 hours of stroke onset or last seen normal and in accordance with local hospital standard of care.\n2. Ages 18-90.\n3. National Institute of Health Stroke Scale (NIHSS) score 6-30\n4. Time of from stroke symptom onset of last seen normal to start of EVT (defined as groin puncture) ≤ 16 hours.\n5. Limited infarct core, as defined below and adapted from the 2018 American Heart Association guidelines\n\n   1. For patients presenting ≤ 6 hours from time of symptom onset or last seen normal, Alberta Stroke Program Early Computed Tomography Score (ASPECTS) ≥ 6\n   2. For patients presenting \\> 6 hours and ≤ 16 hours from time of symptom onset or last seen normal, they must satisfy EITHER ONE of the two following criteria:\n\n   i. Ischemic core by CT Perfusion or MRI/MR Perfusion \\< 70 mL, a ratio of volume of penumbral tissue to infarct core of ≥ 1.8, and and absolute volume of penumbral tissue of ≥ 15 mL OR ii. For patients with NIHSS ≥ 10, infarct core of \\< 31 mL by CT Perfusion or MRI; For patients with NIHSS ≥ 20, infarct core \\< 51 mL.\n6. Subject willing/able to return for protocol required follow up visits.\n7. No significant pre-stroke disability (modified Rankin Score must be ≤ 2).\n8. Females of childbearing potential must have a negative serum or urine pregnancy test.\n9. Patient or patient's legally authorized representative has given Informed Consent according to Good Clinical Practices (GCP) and/or local IRB policies.\n\nExclusion Criteria:\n\n1. Coma on admission (Glasgow Coma Scale \\<8), need for intubation upon ED arrival, or transferred patients who present previously intubated.\n2. Severe agitation or seizures on admission that preclude safe vascular access.\n3. Loss of airway protective reflexes and/or vomiting on admission.\n4. Predicted or known difficult airway.\n5. Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia.\n6. Presumed septic embolus, or suspicion of bacterial endocarditis\n7. Currently participating or has participated in any investigational drug or device study within 30 days.\n8. Inability to follow-up for 90-day assessment.\n9. Known history of allergy to anesthesia drugs.\n10. Known history or family history of malignant hyperthermia","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Peng Roc Chen, MD","affiliation":"The University of Texas Health Science Center, Houston","role":"STUDY_CHAIR"},{"name":"Andrew Barreto, MD","affiliation":"The University of Texas Health Science Center, Houston","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Carlos Artime, MD","affiliation":"The University of Texas Health Science Center, Houston","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Sunil Sheth, MD","affiliation":"The University of Texas Health Science Center, Houston","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Sean Savitz, MD","affiliation":"The University of Texas Health Science Center, Houston","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Claudia Pedroza, PhD","affiliation":"The University of Texas Health Science Center, Houston","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Indiana University College of Medicine","city":"Indianapolis","state":"Indiana","zip":"46202","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"University of Iowa Hospitals and Clinics","city":"Iowa City","state":"Iowa","zip":"52242","country":"United States","geoPoint":{"lat":41.66113,"lon":-91.53017}},{"facility":"Henry Ford Health System","city":"Louisville","state":"Kentucky","zip":"48150","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Rochester Regional Health","city":"Rochester","state":"New York","zip":"14617","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"Wake Forest Baptist Health","city":"Winston-Salem","state":"North Carolina","zip":"27157","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"Geisinger Health","city":"Danville","state":"Pennsylvania","zip":"17822","country":"United States","geoPoint":{"lat":40.96342,"lon":-76.61273}},{"facility":"Temple University","city":"Philadelphia","state":"Pennsylvania","zip":"19122","country":"United States","geoPoint":{"lat":39.95233,"lon":-75.16379}},{"facility":"Memorial Hermann Hospital System - Memorial City Medical Center","city":"Houston","state":"Texas","zip":"77024","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Baylor College of Medicine","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"University of Texas Health Science Center Houston with Memorial Hermann Hospital System - The Medical Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Memorial Hermann Hospital System - The Woodlands Medical Center","city":"The Woodlands","state":"Texas","zip":"77380","country":"United States","geoPoint":{"lat":30.15799,"lon":-95.48938}}]},"referencesModule":{"references":[{"pmid":"35857365","type":"DERIVED","citation":"Tosello R, Riera R, Tosello G, Clezar CN, Amorim JE, Vasconcelos V, Joao BB, Flumignan RL. Type of anaesthesia for acute ischaemic stroke endovascular treatment. Cochrane Database Syst Rev. 2022 Jul 20;7(7):CD013690. doi: 10.1002/14651858.CD013690.pub2."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000000777","term":"Anesthetics"}],"ancestors":[{"id":"D000002492","term":"Central Nervous System Depressants"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M22352","name":"Dexmedetomidine","relevance":"LOW"},{"id":"M17997","name":"Propofol","relevance":"LOW"},{"id":"M11535","name":"Midazolam","relevance":"LOW"},{"id":"M10704","name":"Lidocaine","relevance":"LOW"},{"id":"M1772","name":"Desflurane","relevance":"LOW"},{"id":"M3797","name":"Anesthetics","asFound":"Lymphoma","relevance":"HIGH"},{"id":"M1666","name":"Rocuronium","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M1673","name":"Sevoflurane","relevance":"LOW"},{"id":"M8108","name":"Fentanyl","relevance":"LOW"},{"id":"M7880","name":"Etomidate","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M15867","name":"Succinylcholine","relevance":"LOW"},{"id":"M17110","name":"Vecuronium Bromide","relevance":"LOW"}],"browseBranches":[{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"CNSDep","name":"Central Nervous System Depressants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AdjAn","name":"Adjuvants, Anesthesia"},{"abbrev":"PsychDr","name":"Psychotropic Drugs"},{"abbrev":"AnArAg","name":"Anti-Arrhythmia Agents"},{"abbrev":"ChanBlk","name":"Channel Blockers"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"}]}},"hasResults":false}